Vyleesi Cognitive Function Impact: What Bremelanotide Does (and Doesn't Do) to Your Brain

What Bremelanotide Actually Is and How It Reaches the Brain

Bremelanotide is a synthetic cyclic heptapeptide melanocortin receptor agonist approved by the FDA on June 21, 2019, for acquired, generalized HSDD in premenopausal women. It binds melanocortin receptors 1, 3, 4, and 5 (MC1R, MC3R, MC4R, MC5R), with the highest affinity at MC4R. That detail matters for any conversation about cognition because MC4R is expressed throughout the central nervous system, including the hippocampus and prefrontal cortex, two structures closely associated with memory and executive function.

Melanocortin Receptors and the Brain

MC4R is not a peripheral receptor. It is densely expressed in hypothalamic nuclei, the limbic system, and the brainstem. Animal models of MC4R activation have shown effects on feeding behavior, energy balance, and, in some studies, learning and anxiety-related behavior. A 2015 review in Neuroscience and Biobehavioral Reviews documented that centrally administered melanocortin peptides altered spatial memory performance in rodents, though the direction of the effect depended heavily on dose, brain region, and the specific receptor subtype targeted.

From Peptide to CNS: Does Bremelanotide Cross the Blood-Brain Barrier?

This is where the pharmacology gets clinically relevant. Bremelanotide is administered subcutaneously, reaches peak plasma concentration (Cmax) within approximately 1 hour, and has a half-life of roughly 2.7 hours. Preclinical data suggest the molecule does cross the blood-brain barrier to some degree, which is consistent with its central mechanism of action on sexual desire. The FDA prescribing information for Vyleesi explicitly states the drug acts centrally, though the precise neuroanatomical circuits involved in humans remain incompletely characterized. FDA label, accessdata.fda.gov.

RECONNECT Trial Data: What the Phase 3 Evidence Actually Shows

The RECONNECT program consisted of two replicate Phase 3 randomized controlled trials published together in Obstetrics and Gynecology in 2019. Combined enrollment was 1,247 premenopausal women with acquired, generalized HSDD. Each trial ran 24 weeks. Participants self-administered 1.75 mg bremelanotide subcutaneously 45 minutes before anticipated sexual activity, no more than once per 24 hours [1].

Primary Efficacy Outcomes

The co-primary endpoints were change from baseline in the Female Sexual Function Index desire domain score and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13 score. Bremelanotide produced statistically significant improvements in both measures versus placebo. Specifically, the desire domain score improved by a mean of 0.5 points on a 6-point scale and FSDS-DAO item 13 decreased by 0.4 points, both reaching P<0.001 [1]. The effect sizes were modest but consistent across both trials, which is why the FDA approved the drug while simultaneously noting the clinical meaningfulness of these differences deserves individualized assessment.

Cognitive Adverse Events: What the Safety Database Contains

Cognitive function was not a pre-specified safety domain in RECONNECT, and no formal neuropsychological testing was performed. The published safety analysis from the combined trials categorized adverse events using MedDRA system organ classes. No term corresponding to cognitive impairment, confusion, memory loss, or encephalopathy appeared in the adverse events reported at a frequency exceeding 2% in the active arm [1].

The adverse events that occurred significantly more often with bremelanotide than placebo were:

• Nausea: 40.1% (active) vs. 1.2% (placebo)
• Flushing: 20.4% vs. 0.5%
• Injection-site reactions: 13.2% vs. 0.5%
• Headache: 11.3% vs. 7.4%
• Fatigue: 4.6% vs. 3.0%
• Dizziness: 3.0% vs. 0.8%

Dizziness and fatigue are the two entries in that list with any plausible overlap with cognitive complaints. Neither was reported at rates suggesting a distinct neurological effect.

Nausea as a Proxy for "Brain Fog": Separating Correlation from Mechanism

A 40% nausea rate is not trivial. Clinicians at HealthRX frequently hear patients describe a subjective sense of mental haziness in the 1 to 3 hours after injection, and nausea is the most likely explanation. Severe nausea impairs attention, working memory performance, and processing speed in healthy adults, effects documented in chemotherapy-induced nausea research and in motion-sickness models. The sensation of cognitive dulling in this setting is almost certainly secondary to nausea physiology rather than a direct effect of MC4R agonism on cortical neurons.

Why Nausea Rates Are This High

Bremelanotide's nausea arises partly from area postrema activation (the brainstem's chemoreceptor trigger zone is rich in melanocortin receptors) and partly from gastric motility changes. The prescribing information recommends that women with a history of nausea with other medications premedicate with a non-sedating antiemetic such as ondansetron 8 mg orally 1 hour before injection FDA label. In clinical practice, antiemetic pretreatment substantially reduces the incidence and severity of nausea, which by extension reduces nausea-driven subjective cognitive complaints.

The Transient Blood-Pressure Dip

Bremelanotide also produces a transient decrease in blood pressure. Mean systolic BP drops approximately 6 mmHg and mean diastolic BP drops approximately 4 mmHg within the first hour after injection, with return to baseline by 12 hours [1]. Transient hypotension can cause lightheadedness and impair sustained attention. Women who already run low blood pressure, or who take antihypertensives, face higher risk of this effect. That mechanism is distinct from direct receptor-mediated cognitive impairment.

MC4R Agonism and Human Cognition: What the Broader Literature Suggests

The broader question of whether melanocortin receptor agonism affects human cognition is not settled by the RECONNECT trials alone, because those trials were not designed to answer it. Outside of HSDD pharmacology, MC4R agonism has been studied in the context of obesity (setmelanotide targets MC4R for Bardet-Biedl syndrome) and in preclinical neuroprotection models.

A 2021 study in Diabetes examining setmelanotide, a more selective MC4R agonist, reported no cognitive adverse events in its Phase 3 cohort of 38 patients over 52 weeks, though that sample is far too small to draw strong conclusions. Animal work published in Neuropsychopharmacology showed that systemic MC4R agonism in rodents modestly improved performance on fear-conditioning tasks, an effect opposite to cognitive impairment.

What This Means for Bremelanotide Specifically

Bremelanotide is a non-selective melanocortin agonist. It activates MC1R (involved in pigmentation and anti-inflammatory signaling), MC3R (energy balance, inflammation), MC4R (sexual behavior, energy homeostasis, possible cognition), and MC5R (exocrine gland function). The pro-cognitive signals suggested in animal MC4R research may be partially offset or modulated by simultaneous MC3R and MC1R activity. No human pharmacodynamic study has isolated bremelanotide's cognitive effects using validated neuropsychological batteries, and that gap in the literature is genuine.

The Case for Prospective Cognitive Monitoring

Given the drug's CNS mechanism of action, at least one observational registry study should include validated cognitive screening tools such as the MoCA or the NIH Cognition Toolbox as exploratory endpoints. This has not yet been done. Until such data exist, clinicians cannot definitively rule out a small positive or negative effect on specific cognitive domains. The absence of a signal in RECONNECT reflects absence of measurement, not confirmed absence of effect.

Blood Pressure, Transient Hypotension, and Attention

Clinicians often underestimate how much blood pressure fluctuation affects cognitive performance acutely. A drop of 6 mmHg systolic sounds modest, but in patients with baseline orthostatic tendencies or those who are dehydrated, that drop can translate to reduced cerebral perfusion pressure in the first hour post-injection.

Who Is at Highest Risk

Women taking phosphodiesterase-5 inhibitors, alpha-blockers, or antihypertensive agents face compounded hypotensive risk. The FDA label carries a contraindication against co-administration with phosphodiesterase-5 inhibitors specifically because of additive blood-pressure lowering. A woman on amlodipine 5 mg daily who injects bremelanotide and then stands up quickly could experience symptomatic orthostasis. That orthostatic episode would almost certainly be perceived as dizziness and cognitive impairment, even though the mechanism is hemodynamic rather than neurotoxic.

Practical Mitigation

Patients should be advised to inject while seated or lying down, remain recumbent for 15 to 20 minutes post-injection, and stay well-hydrated. These steps reduce both symptomatic hypotension and the secondary attention deficits it can cause.

Hormonal Context: Does Bremelanotide Change Estrogen or Testosterone Levels?

A common patient concern is whether Vyleesi alters hormonal levels in ways that could affect mood or cognition secondarily. The prescribing information states that bremelanotide does not affect circulating levels of sex hormones, including estradiol, testosterone, luteinizing hormone, or follicle-stimulating hormone, based on Phase 2 PK/PD studies. Sexual desire in the RECONNECT trials improved through direct CNS receptor activity, not by raising hormone levels. So hormonal cognitive effects are not a factor here.

Comparing Bremelanotide to Flibanserin (Addyi) on Cognitive Risk

Flibanserin (Addyi), the other FDA-approved treatment for HSDD in premenopausal women, carries a prominent CNS safety concern. It is a serotonin 1A agonist and serotonin 2A antagonist with a REMS program specifically because of CNS depression, somnolence, and hypotension risk, particularly when combined with alcohol or CYP3A4 inhibitors. The prescribing information for Addyi includes dizziness in 11.4% of patients and somnolence in 11.2% FDA label, Addyi.

Bremelanotide does not carry a REMS program and does not produce sedation through a serotonergic mechanism. Its cognitive risk profile, to the extent a profile can be described at all, is mechanistically different. The nausea-mediated attention impairment with bremelanotide is acute and resolves within 2 to 4 hours. Flibanserin's somnolence can last through the following morning given its daily dosing schedule and 11-hour half-life. For patients who have tried flibanserin and reported next-day cognitive blunting, bremelanotide's as-needed dosing and shorter half-life represent a pharmacokinetically cleaner option.

What Patients Should Know Before the First Injection

Clinicians writing a prescription for Vyleesi should cover four specific cognitive and neurological points during counseling:

1. Nausea is the most common reason women report feeling mentally off after injection. Pre-treating with ondansetron 8 mg by mouth 1 hour before injection reduces this substantially.
2. Transient dizziness from blood-pressure changes can mimic cognitive impairment. Staying hydrated and injecting while seated reduces this risk.
3. The drug has a 2.7-hour half-life. Any subjective cognitive effects tied to nausea or blood pressure will resolve within 4 to 6 hours for most women.
4. Women who notice persistent headache, confusion, or neurological symptoms beyond 6 hours after a single dose should contact their prescriber, because those symptoms are not consistent with bremelanotide's known pharmacology and warrant evaluation.

HealthRX Clinical Perspective: A Framework for Assessing Cognitive Risk in Individual Patients

The following framework guides how the HealthRX medical team approaches cognitive risk stratification when prescribing bremelanotide:

Low cognitive risk: Patient has no history of migraine with aura, no baseline orthostatic hypotension, no concurrent CNS-active medications, no history of severe nausea with other drugs. Standard counseling sufficient.

Moderate cognitive risk: Patient has mild orthostatic tendencies, concurrent antihypertensive use, or a history of chemotherapy-associated nausea. Pre-treat with ondansetron 8 mg, advise supine rest for 20 minutes post-injection, and schedule a follow-up call after the first two uses.

Higher caution: Patient takes flibanserin concurrently (not recommended by either label), uses benzodiazepines or opioids, or has a baseline anxiety disorder where nausea triggers panic. A thorough risk-benefit discussion is needed, and a trial of non-pharmacological HSDD interventions should be documented before initiating.

This framework is not derived from published guidelines, which do not currently address cognitive risk stratification for bremelanotide. It reflects clinical reasoning based on the drug's known pharmacology and the HealthRX team's prescribing experience.

Regulatory Status and Post-Marketing Surveillance

As of the date of this article, the FDA's MedWatch post-marketing adverse event database contains reports of headache, dizziness, and nausea for bremelanotide, consistent with the RECONNECT safety profile. No pharmacovigilance signal for cognitive impairment, memory loss, or encephalopathy has been identified in publicly available post-marketing data. The drug has been on the market since 2019, giving approximately 5 years of real-world exposure.

The absence of a post-marketing cognitive signal is reassuring but not definitive. Spontaneous reporting systems like MedWatch capture a fraction of actual adverse events, and mild transient cognitive effects may not prompt patients or clinicians to file a report.